SlideShare a Scribd company logo
DR. ABHISHEK B L
Moderator-DR. C. S. BHARATHAN


It is the study of physiological & biochemical
effects of drugs & their mechanism of action at
organ system /subcellular /macromolecular levels.



It deals with what the drug does to the body.



Whereas Pharmacokinetics deals with what the body
does to the drug


This may be desirable therapeutic effects or
undesirable adverse effects (A/E)



The A/E may be expected effects of the drug as side
effects or toxicity( Quantitative effect)



Unexpected A/ E are seen as hypersensitivity
( allergy ) or Idiosyncrasy ( Qualitative effect)


Stimulation - Adrenaline on heart/ Pilocarpine on
salivary gland



Depression - Diazepam on CNS/ PPI on Gastric acid




Replacement - Hormones - Insulin , Thyroxin/ levodopa
in parkinsonism



Cytotoxicity - Anticancer drugs , Antibiotics



Irritation




1.
2.
3.
4.




Most drugs act by binding to a particular target
protein as follows:
Receptors
Ion Channels
Enzymes
Carrier or Transport proteins
Certain drugs have no particular target
Eg: Alcohol, GA
Receptor
It is a macromolecular or binding site located on the
surface or inside the effector cell that serves to
recognize the signal molecule / drug & initiate the
response to it, but itself has no other function

Sites of receptors- cell membrane, cytoplasm, nucleus






Paul Ehrlich

The idea that drugs act upon specific
sites (receptive substance) began with
John New Port Langley (1852-1926)
of Cambridge.
The word ‘receptor’ was given by
Paul Ehrlich (1854- 1915).
The receptor concept which forms a
key note in the development of
molecular pharmacology became
firmly established by the quantitative
work of
Alfred Joseph Clark
(1885-1941),
a
professor
of
pharmacology at Kings College
London.


•
•

Drugs acting on receptors may be :
Agonists
Antagonists


Ligand :
Any molecule that binds selectively to a specific
receptor is called ligand



Affinity :
It is the ability of the molecule to bind to a receptor



Intrinsic activity/Efficacy :
It is the ability of the molecule to elicit a response
after binding with the receptor
Agonist









Has both affinity and intrinsic activity
IA= +1
Eg : Adrenaline - α & β receptors,
Morphine- opioid receptors

Antagonist
Has affinty but no intrinsic activity (IA=0).
They oppose the action of agonist
Eg : Propronolol- β blocker,
Atropine-M receptor
PARTIAL AGONIST:




Have affinity & submaximal intrinsic activity
IA =between 0 & +1
Eg : Nalorphine, Pentazocin on opioid receptors

Inverse Agonists:





These drugs have affinity but produces actions
opposite to those produced by agonist.
IA = between 0 & -1
Eg: Beta Carboline on BZD receptor
E= +1

Agonists
Partial
Agonists

E= 0

E= -1

Antagonists

Inverse
Agonists
SPARE RECEPTORS:
These are reserve receptors present in the body,
gets stimulated only at special situations.

SILENT RECEPTORS:
These are receptors to which an agonist binds
but does not produce a response.


Continued use & stimulation of receptors by agonist
drugs may decrease the number and sensitivity of
the receptors.



This phenomenon is called down regulation



Eg: Constant use of β2 agonist (salbutamol) reduce
therapeutic response in Asthma


Continued use and inhibition of receptors by
antagonist drugs, may increase the number and
sensitivity of the receptors.



This phenomenon is called up regulation.



Eg: sudden withdrawal of anti-anginal drug
(Propranolol) may precipitate angina.
1) Ion channel receptor
2) Transmembrane receptor

3) G-protein coupled receptor
4) Nuclear receptor
Receptor which regulate gene transcription.
1. Ion channel linked

2.

Transmembrane linked

3.

G protein linked

4.

Nuclear (gene) linked
-Voltage gated ion channel
-Ligand gated ion channel

-Stretch activated ion channel
-Temperature activated ion channel


Protein pores in the
membrane



Ions include Na+, K+, Ca2+ , Cl.









plasma

Nerves, Skeletal & smooth
muscle cells, cardiac tissue
Channels open when there is
Depolarization of membrane
from its resting potential
Voltage gated Na+ Channeleg. Local An.-lidocaine
Voltage Dependent Ca Channel
eg. Nifedipine
 Protein pores in the

plasma membrane

Ions include Na+, K+, Ca2+ , Cl.
 GABA gated Cl- Ion channel - eg. BZD

 Glutamate gated cation Ch. (NMDA r)-

eg. Ketamine, Galantamine
Action occurs very fast in millisecond
G Protein Coupled
Receptor
GPCR Structure:
• Single polypeptide chain
threaded back and forth
resulting in serpentine
shaped 7 transmembrane
alpha helices with 3 loops
extracellularly & 3 loops
intracellularly.
1

2

3

4

•There’s a G protein
attached
to
the
cytoplasmic side of the
membrane.

6
5

Gα
GDP

7

β
γ

• Amino
terminal
lies
extracellularly & carboxy
terminal on cytosolic side.
Guanine nucleotide binding proteins:
participate in reversible, GTP-mediated interactions.
Common features:
 bind GDP and GTP with high affinity, but adopt different
structure depending on the bound nucleotide.

 GTP-bound complex has high affinity for other proteins
(“acceptor’), affecting their enzymatic activity
 possess intrinsic GTPase activity which converts GTP to
GDP
 Contains ,

and subunits

 -subunit contains the GTP/GDP binding site,




Gs – Adenyl cyclase Stimulator & Ca channel
opener
Gi – Adenyl cyclase Inhibitor & K+ channel
opener



Gq – Phospholipase C activator



Go – Ca channel inhibitor
cAMP

Ca2+/K+

PIP2

Phospholipase C

Adenyl Cyclase
ATP

Gq

Gs- Ca2+
Gi- K+
Go-Ca2+
Transmembrane Receptors

TM Enzyme
Receptor

 Thyrosine kinase
 Thyrosine phosphatase
 Membrane bound GC
receptor

TM Non-Enzyme
Receptor
 Cytokine /JAK STAT
Receptor
 Toll like receptors


Structure:
• Receptors exist as individual

polypeptides
• Each has an extracellular

signal-binding site
• An intracellular tail with a

number of tyrosines & a
single å helix spanning the
membrane
• Receptor action is slow &

occurs in hours

Eg: Insulin receptors, EGF &
NGF, PDGF, ANF, TGF
receptors.
cGMP

IP3













JAK-STAT binding /cytokine receptor
Non enzymatic Transmembrane receptor
JAK-Janus Kinase (cytosolic tyrosine protein
kinase),
STAT- Signal Transducer & Activator of
Transcription (free moving protein)
EX:
Cytokines,
Growth hormones,
Prolactin,
Interferons act through this receptor
TR

TR

TR

TR

TR

TR


Receptors are seen intracellularly in the cytoplasm,
Agonist(drug) cross cell membrane and bind with receptor
and form Drug Receptor complex .



DR complex moves to nucleus, interact with DNA, regulate
gene transcription , synthesise specific proteins which
produce cellular effects.



Nuclear receptor action is very slow and occurs with in hours
or days
Egs: Corticosteroids, Sex hormones ,Thyroxine,
Vitamin D, Vitamin A
HSP90
HSP90

HSP90








Enzyme
Acetyl Cholinesterase
Angiotensin Converting En
Carbonic anhydrase
Cyclo- oxygenase
DHFR
HMG Co A Reductase
Xanthine oxidase

Inhibitors
- Physostigmine
- Captopril
- Acetazolamide
- Aspirin
- Methotrexate
- Simvastatin
- Allopurinol
Transport proteins

Drugs

(Carrier mediated )
1) Choline uptake

-Hemicholinium

2) Monoamine uptake
Antidepressents,
SSRIs

-Tricyclic

3) H+/K+ or Proton pump

-Omeprazole

4) Na+/K+/Cl- symport

-Frusemide
1) Physical
Bulk laxative
eg.- Agar
Osmotic purgative
- Mgso4, Mannitol
Adsorption
- Charcoal
Demulscent
- Glycerine
Astringent
-tannic acids
2) Chemical
-Neutralisation of Gastric Hcl by antacids,
-Chelating agents with Heavy metals
3) Physico-Chemical
-Alcohol









This is a graph showing dose response relation.
Dose is plotted on X-Axis and Response is
plotted on Y-Axis.
There are two types of DRC:
-Graded/simple DRC
- Log DRC
In Log DRC – dose is converted to logarithmic
scale and is plotted
Log DRC is more convenient and used
Simple dose

Drug Concentration

Log Dose




Large variations in doses can not be plotted on a
single graph paper.
Comparison between other drug responses is not
possible


Being logarithmic scale , less space

only is

required for plotting & large variations of dose
can be recorded on single graph paper.



Comparison between different drug responses
are possible


To compare the efficacy & potency of drugs



To distinguish between Competitive &
Noncompetitive antagonism of drugs



For calculating the Therapeutic Index or Safety
margin of drugs






Efficacy is the maximum effect produced by the
drug. The maximum height of DRC shows the
efficacy. Clinically efficacy is more important.
Potency is the amount of drug required to
produce the response. in case of less potent drug ,
DRC shifts to right.
Steeper slope of DRC indicates marked increase
in response with slight increase in dose
Morphine

10mg

Pethidine

100mg

Drug Concentration (log scale)
AG alone

EC50

AG + ANT

EC50

Drug Concentration (log scale)
% Max response

AG alone

AG + NC ANT
AG + higher dose
NC ANT

Log Drug Concentration


The gap between therapeutic effect DRC and adverse
effect DRC defines the safety margin or therapeutic
index (TI)



It can be calculated as ratio between LD50 and ED50



TI = median Lethal Dose
= LD50
median Effective Dose
ED50

TI should be more than one , it indicates safety of drug.
Greater the TI , more will be the safety of the drug


Median effecive dose means the 50% of test
population showing therpeutic effect.



Median lethal dose means the 50% of test
population showing lethal effect.




Drugs with wide TI – Diazepam , Penicillin
Drugs with narrow TI – Digoxin , Lithium,
phenytoin,Theophyllin
This is the dose range of drug bounded by the
dose which produces minimal therapeutic effect
and the dose which produce maximal
acceptable adverse effect.
Also known as Therapeutic Window.
Minimal
therapeutic
effect

Maximal
acceptable
adverse
effect

Therapeutic window

Drug Concentration (log scale)
Combined effect of Drug

Synergism

Antagonism

-Physical Antagonism
Additive
synergism

Supradditive
synergism

-Chemical Antagonism
-Physiological Antagonism
-Receptor Antagonism
1.

Additive synergism:
If the total effect of drugs is equal to sum of their
individual effects, it is called additive synergism
( eg: 2+2 = 4)
Egs: Aspirin + paracetamol (analgesic effect)
Theophyllin + ephedrine (Br.Asthma)

2.

Supra additive synergism :
If the added up effect is greater than sum of their
individual effects, it is called supra-additive
synergism ( eg: 2+2 > 4)
Egs: Levodopa + carbidopa (Parkinsonism)
1.Physical antagonism:
 The effect of one drug is inhibited by physical
property of another drug.
 Eg: Charcoal adsorbs poisons on its surface &
useful in alkaloid poisoning
2.Chemical antagonism :
 Here two drugs interact chemically and one drug
neutralise the effect of the other.
 Egs :Antacids neutralise gastric acidity
Ca EDTA useful in lead poisoning
Here two drugs act on different receptors/ sites; but their
pharmacological effects are opposing each other
functionally
Examples:
 Histamine (H1) produce bronchospasm
 Adrenaline (β2) produce bronchodilation



Insulin reduce blood sugar
Glucagon increase blood sugar
A. Competitive reversible

Both agonists & antagonist drugs compete for same
receptor.



Antagonistic effect is completely reversible.



Eg: Morphine & naloxone on opioid receptor
Adrenalin & Prazosin on alpha receptor
AG alone

EC50

AG + ANT

EC50

Drug Concentration (log scale)
B. Competitive irreversible

both drugs act on the same receptor . But
Antagonistic effect is not reversible .



Eg: Adrenaline & Phenoxybenzamin (α rec.)

C. Non Competitive antagonism 

The drugs act at different sites of the same receptor
or pathway.



Eg: Adrenaline & Verpamil.
% Max response

AG alone

AG + NC ANT
AG + higher dose
NC ANT

Log Drug Concentration
THANK YOU

More Related Content

What's hot

Molecular Pharmacology-Receptor Desensitization
Molecular Pharmacology-Receptor DesensitizationMolecular Pharmacology-Receptor Desensitization
Molecular Pharmacology-Receptor Desensitizationvaruntvs1811
 
Pharmacodynamics (updated 2016) - drdhriti
Pharmacodynamics (updated 2016) - drdhriti Pharmacodynamics (updated 2016) - drdhriti
Pharmacodynamics (updated 2016) - drdhriti
http://neigrihms.gov.in/
 
Relationship between drug concentration and effect and quantitative aspects o...
Relationship between drug concentration and effect and quantitative aspects o...Relationship between drug concentration and effect and quantitative aspects o...
Relationship between drug concentration and effect and quantitative aspects o...
DHINESHKUMAR V
 
Receptors types
Receptors typesReceptors types
Receptors types
Heena Parveen
 
Receptor down regulation
Receptor down regulationReceptor down regulation
Receptor down regulation
Chander K Negi
 
Drug receptors
Drug receptorsDrug receptors
Drug receptors
Dr. Shivesh Gupta
 
Cholinergic antagonists
Cholinergic antagonistsCholinergic antagonists
Cholinergic antagonistscoolboy101pk
 
Pharmacodynamics (Mechanisn of drug action)
Pharmacodynamics (Mechanisn of drug action) Pharmacodynamics (Mechanisn of drug action)
Pharmacodynamics (Mechanisn of drug action)
http://neigrihms.gov.in/
 
Receptors and receptors classification
Receptors and receptors classificationReceptors and receptors classification
Receptors and receptors classification
caucasus international university
 
receptors
receptorsreceptors
receptors
Vijay Salvekar
 
Pharmacology I pharmacodynamics I (Mechanism of Drug Action)
Pharmacology I pharmacodynamics I (Mechanism of Drug Action)Pharmacology I pharmacodynamics I (Mechanism of Drug Action)
Pharmacology I pharmacodynamics I (Mechanism of Drug Action)
Subhash Yende
 
Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
IPMS- KMU KPK PAKISTAN
 
Mechanism of drug action
Mechanism of drug actionMechanism of drug action
Mechanism of drug action
Pranesh Pawaskar
 
Combined effects of Drugs, Pharmacology
Combined effects of Drugs, PharmacologyCombined effects of Drugs, Pharmacology
Combined effects of Drugs, Pharmacology
Dhruva Sharma
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
Jegan Nadar
 
Drug receptor interaction
Drug receptor interactionDrug receptor interaction
Drug receptor interaction
Fariha Shikoh
 
Concepts of agonist and antagonist receptors
Concepts of agonist and antagonist receptorsConcepts of agonist and antagonist receptors
Concepts of agonist and antagonist receptors
Central University of Gujarat, Gandhinagar
 
Mechanism of drug action
Mechanism of drug actionMechanism of drug action
Mechanism of drug actionDr.Vijay Talla
 
Pharmacodynamics..pptx
Pharmacodynamics..pptxPharmacodynamics..pptx
Pharmacodynamics..pptx
KelvinMuriungi3
 
Ion channel RECEPTOR
 Ion channel RECEPTOR Ion channel RECEPTOR
Ion channel RECEPTOR
marymelna1
 

What's hot (20)

Molecular Pharmacology-Receptor Desensitization
Molecular Pharmacology-Receptor DesensitizationMolecular Pharmacology-Receptor Desensitization
Molecular Pharmacology-Receptor Desensitization
 
Pharmacodynamics (updated 2016) - drdhriti
Pharmacodynamics (updated 2016) - drdhriti Pharmacodynamics (updated 2016) - drdhriti
Pharmacodynamics (updated 2016) - drdhriti
 
Relationship between drug concentration and effect and quantitative aspects o...
Relationship between drug concentration and effect and quantitative aspects o...Relationship between drug concentration and effect and quantitative aspects o...
Relationship between drug concentration and effect and quantitative aspects o...
 
Receptors types
Receptors typesReceptors types
Receptors types
 
Receptor down regulation
Receptor down regulationReceptor down regulation
Receptor down regulation
 
Drug receptors
Drug receptorsDrug receptors
Drug receptors
 
Cholinergic antagonists
Cholinergic antagonistsCholinergic antagonists
Cholinergic antagonists
 
Pharmacodynamics (Mechanisn of drug action)
Pharmacodynamics (Mechanisn of drug action) Pharmacodynamics (Mechanisn of drug action)
Pharmacodynamics (Mechanisn of drug action)
 
Receptors and receptors classification
Receptors and receptors classificationReceptors and receptors classification
Receptors and receptors classification
 
receptors
receptorsreceptors
receptors
 
Pharmacology I pharmacodynamics I (Mechanism of Drug Action)
Pharmacology I pharmacodynamics I (Mechanism of Drug Action)Pharmacology I pharmacodynamics I (Mechanism of Drug Action)
Pharmacology I pharmacodynamics I (Mechanism of Drug Action)
 
Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
 
Mechanism of drug action
Mechanism of drug actionMechanism of drug action
Mechanism of drug action
 
Combined effects of Drugs, Pharmacology
Combined effects of Drugs, PharmacologyCombined effects of Drugs, Pharmacology
Combined effects of Drugs, Pharmacology
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
 
Drug receptor interaction
Drug receptor interactionDrug receptor interaction
Drug receptor interaction
 
Concepts of agonist and antagonist receptors
Concepts of agonist and antagonist receptorsConcepts of agonist and antagonist receptors
Concepts of agonist and antagonist receptors
 
Mechanism of drug action
Mechanism of drug actionMechanism of drug action
Mechanism of drug action
 
Pharmacodynamics..pptx
Pharmacodynamics..pptxPharmacodynamics..pptx
Pharmacodynamics..pptx
 
Ion channel RECEPTOR
 Ion channel RECEPTOR Ion channel RECEPTOR
Ion channel RECEPTOR
 

Viewers also liked

Therapeutic Index of drugs and Factors modifying drug action
Therapeutic Index of drugs and Factors modifying drug action Therapeutic Index of drugs and Factors modifying drug action
Therapeutic Index of drugs and Factors modifying drug action
Rahul Kunkulol
 
BIOAVAILABILITY BIOEQUIVALENCE THERAPEUTIC INDEX
BIOAVAILABILITY BIOEQUIVALENCE THERAPEUTIC INDEXBIOAVAILABILITY BIOEQUIVALENCE THERAPEUTIC INDEX
BIOAVAILABILITY BIOEQUIVALENCE THERAPEUTIC INDEX
Asra Hameed
 
Pharmacodynamics 2
Pharmacodynamics 2Pharmacodynamics 2
Pharmacodynamics 2
Khalid Aftab, Ph.D.
 
Toxicity Analysis, LD50, LC50, Chronic Toxic
Toxicity Analysis, LD50, LC50, Chronic ToxicToxicity Analysis, LD50, LC50, Chronic Toxic
Toxicity Analysis, LD50, LC50, Chronic Toxic
Alex Bernadi
 
QUALITY ASSURANCE
QUALITY ASSURANCEQUALITY ASSURANCE
QUALITY ASSURANCE
Pharmaceutical
 

Viewers also liked (7)

Therapeutic Index of drugs and Factors modifying drug action
Therapeutic Index of drugs and Factors modifying drug action Therapeutic Index of drugs and Factors modifying drug action
Therapeutic Index of drugs and Factors modifying drug action
 
BIOAVAILABILITY BIOEQUIVALENCE THERAPEUTIC INDEX
BIOAVAILABILITY BIOEQUIVALENCE THERAPEUTIC INDEXBIOAVAILABILITY BIOEQUIVALENCE THERAPEUTIC INDEX
BIOAVAILABILITY BIOEQUIVALENCE THERAPEUTIC INDEX
 
Pharmacodynamics 2
Pharmacodynamics 2Pharmacodynamics 2
Pharmacodynamics 2
 
Toxicity Analysis, LD50, LC50, Chronic Toxic
Toxicity Analysis, LD50, LC50, Chronic ToxicToxicity Analysis, LD50, LC50, Chronic Toxic
Toxicity Analysis, LD50, LC50, Chronic Toxic
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
 
Pharmacology
PharmacologyPharmacology
Pharmacology
 
QUALITY ASSURANCE
QUALITY ASSURANCEQUALITY ASSURANCE
QUALITY ASSURANCE
 

Similar to Pharmacodynamics

Receptors and signaling pathway dr nipa
Receptors and signaling pathway  dr nipaReceptors and signaling pathway  dr nipa
Receptors and signaling pathway dr nipa
Dr. Nipa Mendapara
 
Pharmacodynamics.ppt
Pharmacodynamics.pptPharmacodynamics.ppt
Pharmacodynamics.ppt
NuhuUsman1
 
Drug Receptors intercaction and Drug antagonism : Dr Rahul Kunkulol's Power p...
Drug Receptors intercaction and Drug antagonism : Dr Rahul Kunkulol's Power p...Drug Receptors intercaction and Drug antagonism : Dr Rahul Kunkulol's Power p...
Drug Receptors intercaction and Drug antagonism : Dr Rahul Kunkulol's Power p...Rahul Kunkulol
 
pharmacodynamics for II MBBS CBME satya 2021
 pharmacodynamics for II MBBS CBME satya 2021 pharmacodynamics for II MBBS CBME satya 2021
pharmacodynamics for II MBBS CBME satya 2021
sathyanarayanan varadarajan
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
ferdousahmed25
 
Mechanism of drug
Mechanism of drugMechanism of drug
Mechanism of drug
anurag795
 
Overview Of Pharmacodynamics 04.15.09
Overview Of Pharmacodynamics 04.15.09Overview Of Pharmacodynamics 04.15.09
Overview Of Pharmacodynamics 04.15.09
pccampo
 
Pharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish PradhanPharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish Pradhan
gundu333pappu
 
Pharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By  Dr Debasish PradhanPharmacodynamics By  Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish Pradhan
Dr Debasish Pradhan
 
Receptor pharmacology
Receptor pharmacologyReceptor pharmacology
Receptor pharmacology
Shweta Tyagi
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
SabaShaikh76
 
Mechanism of drug action,drug receptor phrmacology
Mechanism of drug action,drug receptor phrmacologyMechanism of drug action,drug receptor phrmacology
Mechanism of drug action,drug receptor phrmacology
Reena Gollapalli
 
Pharmacology I pharmacodynamics II (Receptors)
Pharmacology I  pharmacodynamics II (Receptors)Pharmacology I  pharmacodynamics II (Receptors)
Pharmacology I pharmacodynamics II (Receptors)
Subhash Yende
 
General pharmacology 2.1 pharmacodynamics
General pharmacology   2.1 pharmacodynamicsGeneral pharmacology   2.1 pharmacodynamics
General pharmacology 2.1 pharmacodynamics
MangeshBansod2
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
Dr. Pramod B
 
pharmacodynamics I.pptx
pharmacodynamics I.pptxpharmacodynamics I.pptx
pharmacodynamics I.pptx
Mamtanaagar1
 
2022_UMSU PHARMACODYNAMIC 1 2.pptx
2022_UMSU PHARMACODYNAMIC 1  2.pptx2022_UMSU PHARMACODYNAMIC 1  2.pptx
2022_UMSU PHARMACODYNAMIC 1 2.pptx
drRiyan1
 
pharmacodynamics 1.pdf
pharmacodynamics 1.pdfpharmacodynamics 1.pdf
pharmacodynamics 1.pdf
Imtiyaz60
 
pharmacodynamics 1.pptx
pharmacodynamics 1.pptxpharmacodynamics 1.pptx
pharmacodynamics 1.pptx
Imtiyaz60
 
Pharmacodynamics PPT
Pharmacodynamics PPTPharmacodynamics PPT
Pharmacodynamics PPT
Dr. Vijay Prasad
 

Similar to Pharmacodynamics (20)

Receptors and signaling pathway dr nipa
Receptors and signaling pathway  dr nipaReceptors and signaling pathway  dr nipa
Receptors and signaling pathway dr nipa
 
Pharmacodynamics.ppt
Pharmacodynamics.pptPharmacodynamics.ppt
Pharmacodynamics.ppt
 
Drug Receptors intercaction and Drug antagonism : Dr Rahul Kunkulol's Power p...
Drug Receptors intercaction and Drug antagonism : Dr Rahul Kunkulol's Power p...Drug Receptors intercaction and Drug antagonism : Dr Rahul Kunkulol's Power p...
Drug Receptors intercaction and Drug antagonism : Dr Rahul Kunkulol's Power p...
 
pharmacodynamics for II MBBS CBME satya 2021
 pharmacodynamics for II MBBS CBME satya 2021 pharmacodynamics for II MBBS CBME satya 2021
pharmacodynamics for II MBBS CBME satya 2021
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
 
Mechanism of drug
Mechanism of drugMechanism of drug
Mechanism of drug
 
Overview Of Pharmacodynamics 04.15.09
Overview Of Pharmacodynamics 04.15.09Overview Of Pharmacodynamics 04.15.09
Overview Of Pharmacodynamics 04.15.09
 
Pharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish PradhanPharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish Pradhan
 
Pharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By  Dr Debasish PradhanPharmacodynamics By  Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish Pradhan
 
Receptor pharmacology
Receptor pharmacologyReceptor pharmacology
Receptor pharmacology
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
 
Mechanism of drug action,drug receptor phrmacology
Mechanism of drug action,drug receptor phrmacologyMechanism of drug action,drug receptor phrmacology
Mechanism of drug action,drug receptor phrmacology
 
Pharmacology I pharmacodynamics II (Receptors)
Pharmacology I  pharmacodynamics II (Receptors)Pharmacology I  pharmacodynamics II (Receptors)
Pharmacology I pharmacodynamics II (Receptors)
 
General pharmacology 2.1 pharmacodynamics
General pharmacology   2.1 pharmacodynamicsGeneral pharmacology   2.1 pharmacodynamics
General pharmacology 2.1 pharmacodynamics
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
 
pharmacodynamics I.pptx
pharmacodynamics I.pptxpharmacodynamics I.pptx
pharmacodynamics I.pptx
 
2022_UMSU PHARMACODYNAMIC 1 2.pptx
2022_UMSU PHARMACODYNAMIC 1  2.pptx2022_UMSU PHARMACODYNAMIC 1  2.pptx
2022_UMSU PHARMACODYNAMIC 1 2.pptx
 
pharmacodynamics 1.pdf
pharmacodynamics 1.pdfpharmacodynamics 1.pdf
pharmacodynamics 1.pdf
 
pharmacodynamics 1.pptx
pharmacodynamics 1.pptxpharmacodynamics 1.pptx
pharmacodynamics 1.pptx
 
Pharmacodynamics PPT
Pharmacodynamics PPTPharmacodynamics PPT
Pharmacodynamics PPT
 

Recently uploaded

Microsoft - Power Platform_G.Aspiotis.pdf
Microsoft - Power Platform_G.Aspiotis.pdfMicrosoft - Power Platform_G.Aspiotis.pdf
Microsoft - Power Platform_G.Aspiotis.pdf
Uni Systems S.M.S.A.
 
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
BookNet Canada
 
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdfFIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance
 
Removing Uninteresting Bytes in Software Fuzzing
Removing Uninteresting Bytes in Software FuzzingRemoving Uninteresting Bytes in Software Fuzzing
Removing Uninteresting Bytes in Software Fuzzing
Aftab Hussain
 
DevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA ConnectDevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA Connect
Kari Kakkonen
 
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
Neo4j
 
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptx
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptxSecstrike : Reverse Engineering & Pwnable tools for CTF.pptx
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptx
nkrafacyberclub
 
A tale of scale & speed: How the US Navy is enabling software delivery from l...
A tale of scale & speed: How the US Navy is enabling software delivery from l...A tale of scale & speed: How the US Navy is enabling software delivery from l...
A tale of scale & speed: How the US Navy is enabling software delivery from l...
sonjaschweigert1
 
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
SOFTTECHHUB
 
Elevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object CalisthenicsElevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object Calisthenics
Dorra BARTAGUIZ
 
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfObservability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Paige Cruz
 
Monitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR EventsMonitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR Events
Ana-Maria Mihalceanu
 
PHP Frameworks: I want to break free (IPC Berlin 2024)
PHP Frameworks: I want to break free (IPC Berlin 2024)PHP Frameworks: I want to break free (IPC Berlin 2024)
PHP Frameworks: I want to break free (IPC Berlin 2024)
Ralf Eggert
 
By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024
Pierluigi Pugliese
 
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
Neo4j
 
PCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase TeamPCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase Team
ControlCase
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance
 
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdfSAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
Peter Spielvogel
 
National Security Agency - NSA mobile device best practices
National Security Agency - NSA mobile device best practicesNational Security Agency - NSA mobile device best practices
National Security Agency - NSA mobile device best practices
Quotidiano Piemontese
 
The Future of Platform Engineering
The Future of Platform EngineeringThe Future of Platform Engineering
The Future of Platform Engineering
Jemma Hussein Allen
 

Recently uploaded (20)

Microsoft - Power Platform_G.Aspiotis.pdf
Microsoft - Power Platform_G.Aspiotis.pdfMicrosoft - Power Platform_G.Aspiotis.pdf
Microsoft - Power Platform_G.Aspiotis.pdf
 
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
 
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdfFIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
 
Removing Uninteresting Bytes in Software Fuzzing
Removing Uninteresting Bytes in Software FuzzingRemoving Uninteresting Bytes in Software Fuzzing
Removing Uninteresting Bytes in Software Fuzzing
 
DevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA ConnectDevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA Connect
 
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
 
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptx
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptxSecstrike : Reverse Engineering & Pwnable tools for CTF.pptx
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptx
 
A tale of scale & speed: How the US Navy is enabling software delivery from l...
A tale of scale & speed: How the US Navy is enabling software delivery from l...A tale of scale & speed: How the US Navy is enabling software delivery from l...
A tale of scale & speed: How the US Navy is enabling software delivery from l...
 
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
 
Elevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object CalisthenicsElevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object Calisthenics
 
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfObservability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
 
Monitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR EventsMonitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR Events
 
PHP Frameworks: I want to break free (IPC Berlin 2024)
PHP Frameworks: I want to break free (IPC Berlin 2024)PHP Frameworks: I want to break free (IPC Berlin 2024)
PHP Frameworks: I want to break free (IPC Berlin 2024)
 
By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024
 
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
 
PCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase TeamPCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase Team
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
 
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdfSAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
 
National Security Agency - NSA mobile device best practices
National Security Agency - NSA mobile device best practicesNational Security Agency - NSA mobile device best practices
National Security Agency - NSA mobile device best practices
 
The Future of Platform Engineering
The Future of Platform EngineeringThe Future of Platform Engineering
The Future of Platform Engineering
 

Pharmacodynamics

  • 1. DR. ABHISHEK B L Moderator-DR. C. S. BHARATHAN
  • 2.  It is the study of physiological & biochemical effects of drugs & their mechanism of action at organ system /subcellular /macromolecular levels.  It deals with what the drug does to the body.  Whereas Pharmacokinetics deals with what the body does to the drug
  • 3.  This may be desirable therapeutic effects or undesirable adverse effects (A/E)  The A/E may be expected effects of the drug as side effects or toxicity( Quantitative effect)  Unexpected A/ E are seen as hypersensitivity ( allergy ) or Idiosyncrasy ( Qualitative effect)
  • 4.  Stimulation - Adrenaline on heart/ Pilocarpine on salivary gland  Depression - Diazepam on CNS/ PPI on Gastric acid   Replacement - Hormones - Insulin , Thyroxin/ levodopa in parkinsonism  Cytotoxicity - Anticancer drugs , Antibiotics  Irritation 
  • 5.  1. 2. 3. 4.   Most drugs act by binding to a particular target protein as follows: Receptors Ion Channels Enzymes Carrier or Transport proteins Certain drugs have no particular target Eg: Alcohol, GA
  • 6.
  • 7. Receptor It is a macromolecular or binding site located on the surface or inside the effector cell that serves to recognize the signal molecule / drug & initiate the response to it, but itself has no other function Sites of receptors- cell membrane, cytoplasm, nucleus
  • 8.    Paul Ehrlich The idea that drugs act upon specific sites (receptive substance) began with John New Port Langley (1852-1926) of Cambridge. The word ‘receptor’ was given by Paul Ehrlich (1854- 1915). The receptor concept which forms a key note in the development of molecular pharmacology became firmly established by the quantitative work of Alfred Joseph Clark (1885-1941), a professor of pharmacology at Kings College London.
  • 9.  • • Drugs acting on receptors may be : Agonists Antagonists
  • 10.  Ligand : Any molecule that binds selectively to a specific receptor is called ligand  Affinity : It is the ability of the molecule to bind to a receptor  Intrinsic activity/Efficacy : It is the ability of the molecule to elicit a response after binding with the receptor
  • 11. Agonist        Has both affinity and intrinsic activity IA= +1 Eg : Adrenaline - α & β receptors, Morphine- opioid receptors Antagonist Has affinty but no intrinsic activity (IA=0). They oppose the action of agonist Eg : Propronolol- β blocker, Atropine-M receptor
  • 12. PARTIAL AGONIST:    Have affinity & submaximal intrinsic activity IA =between 0 & +1 Eg : Nalorphine, Pentazocin on opioid receptors Inverse Agonists:    These drugs have affinity but produces actions opposite to those produced by agonist. IA = between 0 & -1 Eg: Beta Carboline on BZD receptor
  • 13. E= +1 Agonists Partial Agonists E= 0 E= -1 Antagonists Inverse Agonists
  • 14. SPARE RECEPTORS: These are reserve receptors present in the body, gets stimulated only at special situations. SILENT RECEPTORS: These are receptors to which an agonist binds but does not produce a response.
  • 15.  Continued use & stimulation of receptors by agonist drugs may decrease the number and sensitivity of the receptors.  This phenomenon is called down regulation  Eg: Constant use of β2 agonist (salbutamol) reduce therapeutic response in Asthma
  • 16.  Continued use and inhibition of receptors by antagonist drugs, may increase the number and sensitivity of the receptors.  This phenomenon is called up regulation.  Eg: sudden withdrawal of anti-anginal drug (Propranolol) may precipitate angina.
  • 17. 1) Ion channel receptor 2) Transmembrane receptor 3) G-protein coupled receptor 4) Nuclear receptor Receptor which regulate gene transcription.
  • 18. 1. Ion channel linked 2. Transmembrane linked 3. G protein linked 4. Nuclear (gene) linked
  • 19. -Voltage gated ion channel -Ligand gated ion channel -Stretch activated ion channel -Temperature activated ion channel
  • 20.  Protein pores in the membrane  Ions include Na+, K+, Ca2+ , Cl.     plasma Nerves, Skeletal & smooth muscle cells, cardiac tissue Channels open when there is Depolarization of membrane from its resting potential Voltage gated Na+ Channeleg. Local An.-lidocaine Voltage Dependent Ca Channel eg. Nifedipine
  • 21.  Protein pores in the plasma membrane Ions include Na+, K+, Ca2+ , Cl.  GABA gated Cl- Ion channel - eg. BZD  Glutamate gated cation Ch. (NMDA r)- eg. Ketamine, Galantamine Action occurs very fast in millisecond
  • 22.
  • 24. GPCR Structure: • Single polypeptide chain threaded back and forth resulting in serpentine shaped 7 transmembrane alpha helices with 3 loops extracellularly & 3 loops intracellularly. 1 2 3 4 •There’s a G protein attached to the cytoplasmic side of the membrane. 6 5 Gα GDP 7 β γ • Amino terminal lies extracellularly & carboxy terminal on cytosolic side.
  • 25. Guanine nucleotide binding proteins: participate in reversible, GTP-mediated interactions. Common features:  bind GDP and GTP with high affinity, but adopt different structure depending on the bound nucleotide.  GTP-bound complex has high affinity for other proteins (“acceptor’), affecting their enzymatic activity  possess intrinsic GTPase activity which converts GTP to GDP  Contains , and subunits  -subunit contains the GTP/GDP binding site,
  • 26.
  • 27.   Gs – Adenyl cyclase Stimulator & Ca channel opener Gi – Adenyl cyclase Inhibitor & K+ channel opener  Gq – Phospholipase C activator  Go – Ca channel inhibitor
  • 28.
  • 30.
  • 31. Transmembrane Receptors TM Enzyme Receptor  Thyrosine kinase  Thyrosine phosphatase  Membrane bound GC receptor TM Non-Enzyme Receptor  Cytokine /JAK STAT Receptor  Toll like receptors
  • 32.  Structure: • Receptors exist as individual polypeptides • Each has an extracellular signal-binding site • An intracellular tail with a number of tyrosines & a single å helix spanning the membrane • Receptor action is slow & occurs in hours Eg: Insulin receptors, EGF & NGF, PDGF, ANF, TGF receptors.
  • 34.          JAK-STAT binding /cytokine receptor Non enzymatic Transmembrane receptor JAK-Janus Kinase (cytosolic tyrosine protein kinase), STAT- Signal Transducer & Activator of Transcription (free moving protein) EX: Cytokines, Growth hormones, Prolactin, Interferons act through this receptor
  • 36.  Receptors are seen intracellularly in the cytoplasm, Agonist(drug) cross cell membrane and bind with receptor and form Drug Receptor complex .  DR complex moves to nucleus, interact with DNA, regulate gene transcription , synthesise specific proteins which produce cellular effects.  Nuclear receptor action is very slow and occurs with in hours or days Egs: Corticosteroids, Sex hormones ,Thyroxine, Vitamin D, Vitamin A
  • 38.
  • 39.        Enzyme Acetyl Cholinesterase Angiotensin Converting En Carbonic anhydrase Cyclo- oxygenase DHFR HMG Co A Reductase Xanthine oxidase Inhibitors - Physostigmine - Captopril - Acetazolamide - Aspirin - Methotrexate - Simvastatin - Allopurinol
  • 40. Transport proteins Drugs (Carrier mediated ) 1) Choline uptake -Hemicholinium 2) Monoamine uptake Antidepressents, SSRIs -Tricyclic 3) H+/K+ or Proton pump -Omeprazole 4) Na+/K+/Cl- symport -Frusemide
  • 41. 1) Physical Bulk laxative eg.- Agar Osmotic purgative - Mgso4, Mannitol Adsorption - Charcoal Demulscent - Glycerine Astringent -tannic acids 2) Chemical -Neutralisation of Gastric Hcl by antacids, -Chelating agents with Heavy metals 3) Physico-Chemical -Alcohol
  • 42.      This is a graph showing dose response relation. Dose is plotted on X-Axis and Response is plotted on Y-Axis. There are two types of DRC: -Graded/simple DRC - Log DRC In Log DRC – dose is converted to logarithmic scale and is plotted Log DRC is more convenient and used
  • 44.   Large variations in doses can not be plotted on a single graph paper. Comparison between other drug responses is not possible
  • 45.  Being logarithmic scale , less space only is required for plotting & large variations of dose can be recorded on single graph paper.  Comparison between different drug responses are possible
  • 46.  To compare the efficacy & potency of drugs  To distinguish between Competitive & Noncompetitive antagonism of drugs  For calculating the Therapeutic Index or Safety margin of drugs
  • 47.    Efficacy is the maximum effect produced by the drug. The maximum height of DRC shows the efficacy. Clinically efficacy is more important. Potency is the amount of drug required to produce the response. in case of less potent drug , DRC shifts to right. Steeper slope of DRC indicates marked increase in response with slight increase in dose
  • 48.
  • 50. AG alone EC50 AG + ANT EC50 Drug Concentration (log scale)
  • 51. % Max response AG alone AG + NC ANT AG + higher dose NC ANT Log Drug Concentration
  • 52.  The gap between therapeutic effect DRC and adverse effect DRC defines the safety margin or therapeutic index (TI)  It can be calculated as ratio between LD50 and ED50  TI = median Lethal Dose = LD50 median Effective Dose ED50 TI should be more than one , it indicates safety of drug. Greater the TI , more will be the safety of the drug
  • 53.  Median effecive dose means the 50% of test population showing therpeutic effect.  Median lethal dose means the 50% of test population showing lethal effect.   Drugs with wide TI – Diazepam , Penicillin Drugs with narrow TI – Digoxin , Lithium, phenytoin,Theophyllin
  • 54.
  • 55.
  • 56.
  • 57. This is the dose range of drug bounded by the dose which produces minimal therapeutic effect and the dose which produce maximal acceptable adverse effect. Also known as Therapeutic Window.
  • 59. Combined effect of Drug Synergism Antagonism -Physical Antagonism Additive synergism Supradditive synergism -Chemical Antagonism -Physiological Antagonism -Receptor Antagonism
  • 60. 1. Additive synergism: If the total effect of drugs is equal to sum of their individual effects, it is called additive synergism ( eg: 2+2 = 4) Egs: Aspirin + paracetamol (analgesic effect) Theophyllin + ephedrine (Br.Asthma) 2. Supra additive synergism : If the added up effect is greater than sum of their individual effects, it is called supra-additive synergism ( eg: 2+2 > 4) Egs: Levodopa + carbidopa (Parkinsonism)
  • 61. 1.Physical antagonism:  The effect of one drug is inhibited by physical property of another drug.  Eg: Charcoal adsorbs poisons on its surface & useful in alkaloid poisoning 2.Chemical antagonism :  Here two drugs interact chemically and one drug neutralise the effect of the other.  Egs :Antacids neutralise gastric acidity Ca EDTA useful in lead poisoning
  • 62. Here two drugs act on different receptors/ sites; but their pharmacological effects are opposing each other functionally Examples:  Histamine (H1) produce bronchospasm  Adrenaline (β2) produce bronchodilation   Insulin reduce blood sugar Glucagon increase blood sugar
  • 63. A. Competitive reversible Both agonists & antagonist drugs compete for same receptor.  Antagonistic effect is completely reversible.  Eg: Morphine & naloxone on opioid receptor Adrenalin & Prazosin on alpha receptor
  • 64. AG alone EC50 AG + ANT EC50 Drug Concentration (log scale)
  • 65. B. Competitive irreversible both drugs act on the same receptor . But Antagonistic effect is not reversible .  Eg: Adrenaline & Phenoxybenzamin (α rec.) C. Non Competitive antagonism  The drugs act at different sites of the same receptor or pathway.  Eg: Adrenaline & Verpamil.
  • 66. % Max response AG alone AG + NC ANT AG + higher dose NC ANT Log Drug Concentration